We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » ABBOTT'S NORVIR COST-COMPARISON CHART DRAWS REBUKE FROM DDMAC
ABBOTT'S NORVIR COST-COMPARISON CHART DRAWS REBUKE FROM DDMAC
June 14, 2004
The FDA’s Division of Drug Marketing, Advertising and Communication (DDMAC) has cited Abbott Laboratories for promotional materials that were misleading and lacking complete risk information about the company’s HIV/AIDS drug Norvir.